134 related articles for article (PubMed ID: 31750417)
21. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants.
Scott JF; Brough KR; Grigoryan KV; Muzic JG; Kim GY; Conic RRZ; Hill ST; Brewer JD; Baum CL; Litzow MR; Hogan WJ; Patnaik MS; Hashmi SK; Lazarus HM; Bordeaux JS; Thompson CL; Gerstenblith MR; Lehman JS
JAMA Dermatol; 2020 Jun; 156(6):631-639. PubMed ID: 32267479
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
25. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
Schetelig J; de Wreede LC; van Gelder M; Koster L; Finke J; Niederwieser D; Beelen D; Mufti GJ; Platzbecker U; Ganser A; Heidenreich S; Maertens J; Socié G; Brecht A; Stelljes M; Kobbe G; Volin L; Nagler A; Vitek A; Luft T; Ljungman P; Yakoub-Agha I; Robin M; Kröger N
Leukemia; 2019 Mar; 33(3):686-695. PubMed ID: 30573777
[TBL] [Abstract][Full Text] [Related]
26. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.
Aldoss I; Yang D; Malki MMA; Mei M; Mokhtari S; Artz A; Cao T; Salhotra A; Ali H; Aribi A; Khaled S; Arslan S; Sandhu K; Koller P; Mansour J; Spielberger R; Stein A; Snyder D; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
Transplant Cell Ther; 2021 Mar; 27(3):255.e1-255.e9. PubMed ID: 33781525
[TBL] [Abstract][Full Text] [Related]
28. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.
Sorror ML; Sandmaier BM; Storer BE; Maris MB; Baron F; Maloney DG; Scott BL; Deeg HJ; Appelbaum FR; Storb R
J Clin Oncol; 2007 Sep; 25(27):4246-54. PubMed ID: 17724349
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
30. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
[TBL] [Abstract][Full Text] [Related]
31. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
32. INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION.
Dinan MA; Li Y; Reed SD; Sosa JA
Endocr Pract; 2019 Jan; 25(1):31-42. PubMed ID: 30383499
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
[TBL] [Abstract][Full Text] [Related]
34. Limitations of Applying the Hematopoietic Cell Transplantation Comorbidity Index in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation.
Broglie L; Ruiz J; Jin Z; Kahn JM; Bhatia M; George D; Garvin J; Satwani P
Transplant Cell Ther; 2021 Jan; 27(1):74.e1-74.e9. PubMed ID: 33039515
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Factors for Postrelapse Survival after ex Vivo CD34
Gomez-Arteaga A; Shah GL; Baser RE; Scordo M; Ruiz JD; Bryant A; Dahi PB; Ghosh A; Lahoud OB; Landau HJ; Landgren O; Shaffer BC; Smith EL; Koehne G; Perales MA; Giralt SA; Chung DJ
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2040-2046. PubMed ID: 32712326
[TBL] [Abstract][Full Text] [Related]
37. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
38. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
Hu B; Lin X; Lee HC; Huang X; Tidwell RSS; Ahn KW; Hu ZH; Jabbour E; Verstovsek S; Ravandi F; Garcia-Manero G; Kharfan-Dabaja MA; Hossain NM; Marks DI; Kamble RT; Inamoto Y; Kindwall-Keller T; Saad A; Litzow MR; Savani BN; Hale GA; Bacher U; Gerds AT; Liesveld JL; Ustun C; Olsson RF; Daly A; Grunwald MR; Solh M; DeFilipp Z; Aljurf M; Wirk B; Akpek G; Nishihori T; Cerny J; Seo S; Hsu JW; Champlin R; de Lima M; Alyea E; Popat U; Sobecks R; Scott BL; Kantarjian H; Cortes J; Saber W
Leuk Lymphoma; 2020 Dec; 61(12):2811-2820. PubMed ID: 32662346
[TBL] [Abstract][Full Text] [Related]
39. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
40. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
